Alzinova AB (publ) (ticker: ALZ) today announces that the company appoints Erik Kullgren as interim CFO due to the fact that the company's current CFO, Håkan Skogström, will retire on March 27. The process of recruiting a permanent CFO is ongoing.

Alzinova has previously announced that CFO Håkan Skogström wishes to retire during 2024 and can now announce that it will be on March 27. Erik Kullgren will act as interim CFO until a permanent successor has been appointed. The process of recruiting a permanent CFO is ongoing.

Erik Kullgren has a Degree of Master of Science in Business and Economics from the School of Business, Economics and Law at the University of Gothenburg, and has extensive experience as CFO for both listed and unlisted companies. He has also been CEO of Reguity Group AB and Dunross & Co AB. Currently, Erik Kullgren runs his own consulting company where he acts as CFO for, among others, Medfield Diagnostics AB and Shortcut Media AB.

"We would once again like to thank Håkan for his excellent work and it is with pleasure that we welcome Erik. Erik has a solid experience and relevant expertise that will be excellent in this transition period until we have recruited a permanent CFO", says Alzinova's CEO Kristina Torfgård.

For more information, please contact:
Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail:  kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Attachments
Alzinova appoints Erik Kullgren as interim CFO

© Modular Finance, source Nordic Press Releases